Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

JOHNSON & JOHNSON

(JNJ)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Johnson & Johnson : Janssen Seeks FDA Approval of New Darzalex Subcutaneous Formulation

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/12/2019 | 12:24pm EDT

By Stephen Nakrosis

The Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ) said Friday it submitted an application with the U.S. Food and Drug Administration seeking approval of its new subcutaneous formulation of Darzalex, or daratumumab, for certain patients with multiple myeloma.

Janssen said the Biologics License Application was supported by data from its Phase 3 Columba study, which included 522 patients, and data from the Phase 2 Pleiades study, which included 240 patients.

"The Darzalex subcutaneous formulation showed non-inferiority to the existing IV formulation, both as a monotherapy and in combination with common background therapies, while administered with a considerably shorter infusion time. We look forward to working closely with the FDA in their review of the data supporting this regulatory application," said Craig Tendler, vice president, clinical development and global medical affairs, oncology, Janssen Research & Development.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
02:48aJOHNSON & JOHNSON : J&J Fights To Restrict Talc-Suit Testimony
DJ
07/21JOHNSON & JOHNSON : Faces Key Test in Defense Against Talc-Safety Lawsuits
DJ
07/19JOHNSON & JOHNSON INVESTIGATION UPDA : Kahn Swick & Foti, LLC Continues to Inves..
BU
07/19JOHNSON & JOHNSON : J&J's Janssen Seeks Europe OK For Subcutaneous Darzalex in M..
DJ
07/18JOHNSON & JOHNSON : Oklahoma County seeking lawsuit against opioid manufacturers
AQ
07/18JOHNSON & JOHNSON : DRC rejects clinical trial for experimental Ebola vaccine
AQ
07/17JOHNSON & JOHNSON : Extends Long-Standing Donation Program to Support Global Eff..
AQ
07/17GENMAB : Announces Net Sales of DARZALEX for Second Quarter of 2019
AQ
07/17JOHNSON & JOHNSON : 's Baltic net profits down 42% to EUR 1.2 million
AQ
07/17J&J Lifts Forecast As Suits Weigh On Its Shares -- WSJ
DJ
More news
Financials (USD)
Sales 2019 81 594 M
EBIT 2019 25 389 M
Net income 2019 18 319 M
Debt 2019 6 116 M
Yield 2019 2,91%
P/E ratio 2019 19,2x
P/E ratio 2020 17,0x
EV / Sales2019 4,26x
EV / Sales2020 4,00x
Capitalization 342 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 149,00  $
Last Close Price 128,64  $
Spread / Highest target 31,4%
Spread / Average Target 15,8%
Spread / Lowest Target -3,61%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Charles O. Prince Independent Director
William David Perez Independent Director
Anne M. Mulcahy Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-0.32%345 980
PFIZER-2.02%237 451
ROCHE HOLDING LTD.8.73%230 263
ROCHE HOLDING10.69%230 263
NOVARTIS24.78%216 273
MERCK AND COMPANY6.52%209 550